Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;19(23):15974.
doi: 10.3390/ijerph192315974.

Adults with Intellectual Disability and Autism Spectrum Disorder: What Is the Evidence around the Use of Polypharmacy

Jane M McCarthy  1   2 , Eddie Chaplin  3
Affiliations
Review

Adults with Intellectual Disability and Autism Spectrum Disorder: What Is the Evidence around the Use of Polypharmacy

Jane M McCarthy et al. Int J Environ Res Public Health. .

Abstract

A review on the mental health needs of adults with intellectual disability (ID) and autism spectrum disorder (ASD) published just over 10 years ago found a limited evidence base for pharmacological intervention in this group. The aim of this paper was therefore to review the evidence in the subsequent 10 years, with a focus on polypharmacy use in adults who have both ID and ASD. A critical literature review of key papers published from 2009 to 2021 was undertaken on adults with both ID and ASD and related to psychopharmacology, polypharmacy, antipsychotics, antidepressants, mood stabilisers and anxiolytics interventions in improving symptoms. After excluding articles for lack of relevance, a review with a focus on the use of polypharmacy was carried out on the retrieved results. Four papers were identified as relevant to adults with both ID and ASD. Three main themes were identified in the review, including the application of pharmacogenetics, the influence of national policy on prescribing practices and safety concerns in a population with multiple health comorbidities. The past decade has produced a small increase in the evidence base on psychopharmacology use in adults with ID and ASD. However, more evidence on the effectiveness and impact of long-term polypharmacy use is required.

Keywords: autism spectrum disorder; comorbidity; intellectual disability; polypharmacy; prescribing; psychopharmacology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prisma systematic review flow diagram.
See this image and copyright information in PMC

References

    1. Underwood L., McCarthy J., Tsakanikos E. Mental health of adults with autism spectrum disorders and intellectual disability. Curr. Opin. Psychiatry. 2010;23:421–426. doi: 10.1097/YCO.0b013e32833cfc18. - DOI - PubMed
    1. Payne R.A. The epidemiology of polypharmacy. Clin. Med. 2016;16:465–469. doi: 10.7861/clinmedicine.16-5-465. - DOI - PMC - PubMed
    1. Lunsky Y., Modi M. Predictors of Psychotropic Polypharmacy Among Outpatients With Psychiatric Disorders and Intellectual Disability. Psychiatr. Serv. 2018;69:242–246. doi: 10.1176/appi.ps.201700032. - DOI - PubMed
    1. Deb S., Unwin G., Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J. Intellect. Disabil. Res. 2014;59:11–25. doi: 10.1111/jir.12119. - DOI - PubMed
    1. Deb S.S., Bertelli M.O., Rossi M. Psychopharmacology. In: Bertelli M.O., Deb S.S., Munir K., Hassiotis A., Salvador-Carulla L., editors. Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder. Springer Nature; New York, NY, USA: 2022.

Substances